UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT

     PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

       Date of Report (Date of earliest event reported): October 24, 2006

                              ALFACELL CORPORATION
             (Exact name of registrant as specified in its charter)

                                     0-11088
                            (Commission File Number)

             Delaware                                    22-2369085
   (State or other jurisdiction of         (I.R.S. Employer Identification No.)
    incorporation)

               225 BELLEVILLE AVENUE, BLOOMFIELD, NEW JERSEY 07003
             (Address of principal executive offices, with zip code)

                                 (973) 748-8082
              (Registrant's telephone number, including area code)

                                 NOT APPLICABLE
          (Former name or former address, if changed since last report)


     Check the  appropriate  box below if the Form 8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (SEE General Instruction A.2. below):

     [ ]  Written communications pursuant to Rule 425 under the  Securities
          Act (17 CFR 230.425)

     [ ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act
          (17 CFR 240.14a-12)

     [ ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the
          Exchange Act (17 CFR 240.14d-2(b))

     [ ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the
          Exchange Act (17 CFR 240.13e-4(c))


                                       1


ITEM 8.01         OTHER EVENTS.

     On October 24, 2006,  Alfacell  Corporation (the "Company")  issued a press
release  announcing  results from  further  detailed  analysis of the  Company's
previously reported Phase IIIa clinical trial of ONCONASE(R) (ranpirnase) versus
doxorubicin for the treatment of unresectable  malignant  mesothelioma  (UMM). A
copy of the press  release is filed as  Exhibit  99.1  hereto  and  incorporated
herein by reference.

ITEM 9.01         FINANCIAL STATEMENTS AND EXHIBITS.

(c)      Exhibits.

99.1     Press release of Alfacell Corporation dated October 24, 2006.


                                       2



                                   SIGNATURES



     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.


                                                ALFACELL CORPORATION



Date:  October 24, 2006                          By:  /s/ Robert D. Love
                                                      Robert D. Love
                                                      Chief Financial Officer


                                       3